[go: up one dir, main page]

CL2008001620A1 - Induccion de fenotipo tolerogenico en celulas dendriticas maduras - Google Patents

Induccion de fenotipo tolerogenico en celulas dendriticas maduras

Info

Publication number
CL2008001620A1
CL2008001620A1 CL2008001620A CL2008001620A CL2008001620A1 CL 2008001620 A1 CL2008001620 A1 CL 2008001620A1 CL 2008001620 A CL2008001620 A CL 2008001620A CL 2008001620 A CL2008001620 A CL 2008001620A CL 2008001620 A1 CL2008001620 A1 CL 2008001620A1
Authority
CL
Chile
Prior art keywords
induction
dendritic cells
mature dendritic
tolerogenic phenotype
tolerogenic
Prior art date
Application number
CL2008001620A
Other languages
English (en)
Inventor
Herrera Jose M Carballido
Vries Jan E De
Ulf Korthaeuer
Maria Grazia Roncarolo
Silvia Adriana Gregori
Original Assignee
Novartis Ag
Fond Centro San Raffaele Del Monte Tabor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Fond Centro San Raffaele Del Monte Tabor filed Critical Novartis Ag
Publication of CL2008001620A1 publication Critical patent/CL2008001620A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Método para modular la función de las células dendríticas que comprende exponerlas a una molécula de enlace cd45ro/rb; composición farmacéutica que las comprende; y uso de dichas células para el tratamiento y/o profilaxis de una enfermedad asociada con enfermedad autoinmune, rechazo de trasplante, entre otras.
CL2008001620A 2007-06-05 2008-06-04 Induccion de fenotipo tolerogenico en celulas dendriticas maduras CL2008001620A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07109672 2007-06-05

Publications (1)

Publication Number Publication Date
CL2008001620A1 true CL2008001620A1 (es) 2009-02-20

Family

ID=39721982

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001620A CL2008001620A1 (es) 2007-06-05 2008-06-04 Induccion de fenotipo tolerogenico en celulas dendriticas maduras

Country Status (17)

Country Link
US (1) US20100183602A1 (es)
EP (1) EP2160410A1 (es)
JP (1) JP2010529078A (es)
KR (1) KR20100035643A (es)
CN (1) CN101687928A (es)
AU (1) AU2008258646A1 (es)
BR (1) BRPI0812205A2 (es)
CA (1) CA2689570A1 (es)
CL (1) CL2008001620A1 (es)
EA (1) EA200901621A1 (es)
IL (1) IL202230A0 (es)
MA (1) MA31667B1 (es)
MX (1) MX2009013220A (es)
TN (1) TN2009000494A1 (es)
TW (1) TW200907061A (es)
WO (1) WO2008148761A1 (es)
ZA (1) ZA200908089B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067237B2 (en) 2005-12-13 2011-11-29 President And Fellows Of Harvard College Scaffolds for cell transplantation
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
JP5690143B2 (ja) 2008-02-13 2015-03-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 持続的細胞プログラミング装置
US8728456B2 (en) 2009-07-31 2014-05-20 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
EP2305277A1 (en) * 2009-09-18 2011-04-06 Forskarpatent I Syd AB Use of tolerogenic dendritic cells in treatment and prevention of atherosclerosis
EP3620185A1 (en) 2010-10-06 2020-03-11 President and Fellows of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
AU2012249456A1 (en) 2011-04-28 2013-10-31 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
MX2013012598A (es) 2011-04-29 2014-08-18 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para eliminar linfocitos t efectores específicos para un antígeno.
WO2012167230A1 (en) 2011-06-03 2012-12-06 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
WO2013036303A2 (en) * 2011-09-06 2013-03-14 Selecta Biosciences, Inc. Induced tolerogenic dendritic cells to reduce systemic inflammatory cytokines
LT2838515T (lt) 2012-04-16 2020-03-10 President And Fellows Of Harvard College Mezoporinės silico dioksido kompozicijos, skirtos imuninio atsako moduliavimui
KR20240119155A (ko) 2013-05-03 2024-08-06 셀렉타 바이오사이언시즈, 인크. 감소 또는 증진된 약역학적 효과를 위한 관용유발 합성 나노담체 및 치료 거대분자
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
MX2017002935A (es) 2014-09-07 2017-05-30 Selecta Biosciences Inc Metodos y composiciones para atenuar las respuestas inmunes anti-vector de transferencia viral de saltado de exones.
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
EP3280464A4 (en) 2015-04-10 2018-09-26 President and Fellows of Harvard College Immune cell trapping devices and methods for making and using the same
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
FI3484448T3 (fi) 2016-07-13 2025-06-16 Harvard College Antigeenia esitteleviä solumimeettisiä tukirakenteita ja menetelmiä niiden valmistamiseksi ja käyttämiseksi
AU2017305345B2 (en) 2016-08-02 2024-09-05 President And Fellows Of Harvard College Biomaterials for modulating immune responses
HUE072005T2 (hu) 2017-03-11 2025-10-28 Cartesian Therapeutics Inc Gyulladásgátlókkal és immunszupresszánst tartalmazó szintetikus nanohordozókkal történõ kombinált kezeléssel összefüggõ eljárások és készítmények
WO2019222547A1 (en) * 2018-05-17 2019-11-21 The Board Of Trustees Of The Leland Stanford Junior University Receptor inhibition by phosphatase recruitment
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103389D0 (en) * 2001-02-12 2001-03-28 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
BRPI0812205A2 (pt) 2014-11-25
EA200901621A1 (ru) 2010-06-30
AU2008258646A1 (en) 2008-12-11
JP2010529078A (ja) 2010-08-26
TN2009000494A1 (en) 2011-03-31
MX2009013220A (es) 2010-04-09
US20100183602A1 (en) 2010-07-22
TW200907061A (en) 2009-02-16
CN101687928A (zh) 2010-03-31
WO2008148761A1 (en) 2008-12-11
KR20100035643A (ko) 2010-04-05
EP2160410A1 (en) 2010-03-10
MA31667B1 (fr) 2010-09-01
ZA200908089B (en) 2010-07-28
CA2689570A1 (en) 2008-12-11
IL202230A0 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
CL2008001620A1 (es) Induccion de fenotipo tolerogenico en celulas dendriticas maduras
CY1121857T1 (el) Ενωσεις οι οποιες επεκτεινουν αιμοποιητικα βλαστοκυτταρα
UY31275A1 (es) Anticuerpos anti-cd37
AR077199A1 (es) Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia
CO6311008A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+
CL2012002882A1 (es) Compuestos derivados de 5,7- sustituido -imidazol [1,2-c] pirimidinas, inhibidores de jak-quinasa; proceso de preparacion; composicion farmaceutica; y su uso para tratar una enfermedad autoinmunitaria o inflamatoria, el rechazo de transplante de organos, tejidos o celulas en un mamifero.
ES2479542T1 (es) Métodos y composiciones para su uso en terapias celulares
AR086272A2 (es) Anticuerpos anti-factor d humanizados y sus usos
MX2009013706A (es) Celulas multipotentes/pluripotentes y metodos relacionados.
SV2008002980A (es) Composiciones y metodos de uso para anticuerpos de dickkopf-1 y/0 -4
AR077333A1 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina -2 humana
CO6410314A2 (es) Proteínas de unión a il-17
MX2019002288A (es) Suspensión celular para usarse en el tratamiento de la arteriopatía periférica de las extremidades inferiores.
BR112015017174A2 (pt) preparação de enxertos de nervo de tecido manipulado com matriz extracelular modificada para reparo de lesão de nervo periférico
CL2011003160A1 (es) Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras.
CL2009000985A1 (es) Composicion oftalmica que comprende entre 0,16 y 0,19% p/v de un galactomanano, alrededor de 0,7% p/v de un borato, cis-diol y menos de 5 ppm de concentracion de cationes divalentes; y su uso para lubricar el ojo.
CL2012000809A1 (es) Uso de una composicion que comprende bifidobacterium atcc baa-999 que sirve para la preparacion de un medicamento util para apoyar la perdida de peso y/o mantener el peso en humanos y/o animales maduros.
CL2008002984A1 (es) Composicion farmaceutica que comprende micofenolato sodico y su uso para el tratamiento y/o prevencion en enfermedades autoinmunes tales como el rechazo de aloinjertos o xenoinjertos de organos, celulas o tejidos y como antiinflamatorio.
GT200800065A (es) Métodos y composiciones para modular la hemostasia
BRPI0506839A (pt) composições e métodos para induzir a cardiomiogênese
GT200900217A (es) Nuevos compuestos triciclicos, un proceso para su preparacion y las composiciones farmaceuticas que los contienen.
CR9114A (es) 2-alcoxi-3,4,5-trihydroxi-alquimidas, su preparacion composicones que las contienen y su utilizacion
AR084263A1 (es) Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen)
CL2010000774A1 (es) Medio para el cultivo de celulas de mamiferos que comprende ademas de los nutrientes habituales de los medios de cultivo basales para cultivo de celulas de mamiferos, sobrenadante de la fraccion ii+iii del plasma humano segun el metodo de cohn; procedimiento de preparacion; y su uso.
GT200900045A (es) Sales de bencimidazolilo piridilo eteres y las formulaciones del mismo